SUBSCRIBE
SUBSCRIBE
News   Drug Development

OncoMethylome Sciences S.A. in Deal for Brain Tumor Trial

April 16, 2009 | 
1 min read
BRUSSELS, April 16 (Reuters) - OncoMethylome Sciences SA begins MGMT gene promoter methylation testing in a recently started Phase III clinical trial for the U.S.-based, Radiotherapy Oncology Group in newly diagnosed brain tumors (glioblastoma).
Clinical research Phase 3 Europe
MORE ON THIS TOPIC
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker
Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).
FDA
FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision
February 18, 2026
 · 
3 min read
 · 
Heather McKenzie
Podcast
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
February 18, 2026
 · 
1 min read
 · 
Heather McKenzie
illustration of doubtful man thinks whether to jump to the other side of the mountain, dilemma concept
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
 · 
3 min read
 · 
Annalee Armstrong